Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy?

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1696-1705

  Bader, Peter ^a   Kreyenberg, Hermann ^a   Hoelle, Walter ^a   Dueckers, Gregor ^a   Handgretinger, Rupert ^a   Lang, Peter ^a   Kremens, Bernhard ^a   Dilloo, Dagmar ^a   Sykora, Karl Walter ^a   Schrappe, Martin ^a   Niemeyer, Charlotte ^a   Von Stackelberg, Arend ^a   Gruhn, Bernd ^a   Henze, Günter ^a   Greil, Johann ^a   Niethammer, Dietrich ^a   Dietz, Klaus ^a   Beck, James F ^a   Klingebiel, Thomas ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CANCER RELAPSE; CANCER SURVIVAL; CHIMERA; CONTROLLED STUDY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SERIAL ANALYSIS OF GENE EXPRESSION; SHORT TANDEM REPEAT; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; CHILD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENETICS; INFANT; LYMPHOCYTE TRANSFUSION; MALE; MULTICENTER STUDY; NEWBORN; PATHOLOGY; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; STEM CELL TRANSPLANTATION;

IMMUNOSUPPRESSIVE AGENT;

CHILD; CHILD, PRESCHOOL; CHIMERA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 2442704411     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.198     Document Type: Article

References (56)

1. Rivera GK, Pinkel D, Simone JV, et al: Treatment of acute lymphoblastic leukemia: 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 329:1289-1295, 1993
2. Barrett AJ, Locatelli F, Treleaven JG, et al: Second transplants for leukaemic relapse after bone marrow transplantation: High early mortality but favourable effect of chronic GVHD on continued remission-A report by the EBMT Leukaemia Working Party. Br J Haematol 79: 567-574, 1991
3. Munoz A, Badell I, Olive T, et al: Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: Long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON). Haematologica 87:331-332, 2002
4. Bosi A, Laszlo D, Labopin M, et al: Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 19:3675-3684, 2001
5. Chessells JM: Treatment of childhood acute lymphoblastic leukaemia: Present issues and future prospects. Blood Rev 6:193-203, 1992
6. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050, 1995
7. Kolb HJ, Mittermuller J, Clemm C, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990
8. Imamura M, Hashino S, Tanaka J: Graft-versus-leukemia effect and its clinical implications. Leuk Lymphoma 23:477-492, 1996
9. Mehta J. Powles R, Kulkarni S, et al: Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: Single-center experience of 32 adult patients. Bone Marrow Transplant 20:129-135, 1997
10. Porter DL, Roth MS, Lee SJ, et al: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 18: 975-980, 1996
11. Porter DL, Connors JM, Van Deerlin VM, et al: Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 17:1234-1237, 1999
12. Bertz H, Burger JA, Kunzmann R, et al: Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect. Leukemia 11:281-283, 1997
13. Verdonck LF, Lokhorst HM, Dekker AW, et al: Graft-versus-myeloma effect in two cases. Lancet 347:800-801, 1996
14. Sosman JA, Sondel PM: The graft-vs.-leukemia effect: Implications for post-marrow transplant antileukemia treatment. Am J Pediatr Hematol Oncol 15:185-195, 1993
15. Collins RH Jr, Rogers ZR, Bennett M, et al: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10: 391-395, 1992
16. Abraham R, Szer J, Bardy P, et al: Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplant 20:773-777, 1997
17. Mehta J, Powles R, Singhal S, et al: Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 16: 133-137, 1995
18. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195-2204, 1996
19. Mehta J, Powles R, Treleaven J, et al: Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 19:709-719, 1997
20. Gardiner N, Lawler M, O'Riordan JM, et al: Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Bone Marrow Transplant 21:711-719, 1998
21. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response? Bone Marrow Transplant 15:591-594, 1995
22. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268, 1995
23. Bacigalupo A, Soracco M, Vassallo F, et al: Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 19:927-932, 1997
24. Pati AR, Godder K, Lamb L, et al: Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 15:979-981, 1995
25. Or R, Ackerstein A, Nagler A, et al: Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. J Immunother 21:447-453, 1998
26. Johnson BD, Truitt RL: Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85: 3302-3312, 1995
27. van Rhee F, Lin F, Cullis JO, et al: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-3383, 1994
28. Bader P, Holle W, Klingebiel T, et al: Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: The impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 19:697-702, 1997
29. Bader P, Beck J, Frey A, et al: Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 21:487-495, 1998
30. Bader P, Holle W, Klingebiel T, et al: Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res 16:1759-1763, 1996
31. Kreyenberg H, Holle W, Mohrle S, et al: Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: The Tuebingen experience. Leukemia 17:237-240, 2003
32. Bader P, Klingebiel T, Schaudt A, et al: Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children. Leukemia 13:2079-2086, 1999
33. Klingebiel T, Niethammer D, Dietz K, et al: Progress in chimerism analysis in childhood malignancies: The dilemma of biostatistical considerations and ethical implications. Leukemia 15: 1989-1991, 2001
34. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295-304, 1974
35. Klingebiel T, Schlegel PG: GVHD: Overview on pathophysiology, incidence, clinical and biological features. Bone Marrow Transplant 21: S45-S49, 1998 (suppl 2)
36. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Stat Assoc 58:457-481, 1958
37. Shlomchik WD, Emerson SG: The immunobiology of T cell therapies for leukemias. Acta Haematol 96:189-213, 1996
38. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
39. Weiden PL, Flournoy N, Thomas ED, et al: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068-1073, 1979
40. Passweg JR, Tiberghien P, Cahn JY, et al: Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 21:153-158, 1998
41. Marmont AM, Horowitz MM, Gale RP, et al: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130, 1991
42. Bader P, Stoll K, Huber S, et al: Characterization of lineage-specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Br J Haematol 108:761-768, 2000
43. Sykes M, Sachs DH: Bone marrow transplantation as a means of inducing tolerance. Semin Immunol 2:401-417, 1990
44. Nikolic B, Sykes M: Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol 9:634-640, 1997
45. Locatelli F, Zecca M, Rondelli R, et al: Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 95:1572-1579, 2000
46. Kolb HJ, Holler E: Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 9:139-145, 1997
47. Kolb HJ: Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation: EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 74:321-329, 1998 (suppl 2)
48. Collins RH Jr, Shpilberg O, Drobyski WR, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997
49. Luznik L, Fuchs EJ: Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 9:123-137, 2002
50. Riddell SR, Murata M, Bryant S, et al: T-cell therapy of leukemia. Cancer Control 9:114-122, 2002
51. Bader P, Beck J, Schlegel PG, et al: Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: Is there an option to prevent relapse? Bone Marrow Transplant 20:79-81, 1997
52. Lion T, Daxberger H, Dubovsky J, et al: Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 15:307-310, 2001
53. Thiede C, Bornhauser M, Oelschlagel U, et al: Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 15: 293-302, 2001
54. Thiede C, Florek M, Bornhauser M, et al: Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 23:1055-1060, 1999
55. Molloy K, Goulden N, Lawler M, et al: Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors. Blood 87:3027-3031, 1996
56. Schattenberg A, De Witte T, Salden M, et al: Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood 73:1367-1372, 1989